7th Annual MarketsandMarkets Next-Gen Immuno-Oncology

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman Andrea Bisso, Director of Pharmacology , Gadeta	08:55 - 09:00
New Antibody Formats & Cellular Therapy
Keynote Presentation: New Modes of T Cell Recognition and Novel Broadly-Expressed T Cell Epitopes by Dissection of Cancer Immunotherapy Success Andrew Sewell , Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University	09:00 - 09:30
End-to-end proteomics services for discovery, validation and deployment of novel biomarkers in drug development and clinical trials Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	09:30 - 10:00
Engineering Antibody-Cytokine Fusion Proteins (Immunocytokines) for cancer therapy Roberto De Luca, Head, Antibody Therapeutics Research, Philogen	10:00 - 10:30
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:30 - 11:15
Specific targeting of solid tumors with novel Gamma Delta TCRs Andrea Bisso, Director of Pharmacology , Gadeta	11:15 - 11:45
Mapping the cellular architecture of the tumor microenvironment with novel label-free hyperplex immunofluorescence Angelo Da Rosa, Technical Sales Specialist, Lunaphore	11:45 - 12:15
Advancing Immuno-oncology and cell therapies from discovery to market through state of the art single cell analysis Gianluca Rotta, Scientific Affairs Manager, Becton Dickinson	12:15 - 12:45
Target Discovery within Drug Development Life Cycle Liu Chuan, EU Business Head, Sanyou Bio	12:45 - 13:15
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:15 - 14:15
Myeloid checkpoint blockade to recruit neutrophils as effector cells in antibody-based immunotherapy Thomas Valerius, Assistant Professor, University of Kiel	14:15 - 14:45
CAR T-cell immunotherapy in solid tumours: Parallel learning from the clinic and the lab. Fahima Kausar, Team Lead, Leucid Bio	14:45 - 15:15
TCR/BCR Repertoire Analysis and Other Approaches for the Discovery of Drug Targets, Resistance Mechanisms, and Biomarkers Paul Diehl, Chief Operating Officer, Cellecta	15:15 - 15:45
Afternoon Refreshments and Poster Presentations \| One-to-One Networking Meetings	15:45 - 16:30
In Vitro Assays Modelling T Cell Exhaustion and Tumour Associated Macrophages to Support Assessment of Potential Cancer Immunotherapies Mark Barbour, Senior Scientist, Malvern Panalytical	16:30 - 17:00
Development of costimulatory antigen receptors to improve TIL therapies John Bridgeman, Director, Discovery Research, Instil Bio	17:00 - 17:30
Neo-X-Prime™: Bispecific Tumor Antigen Conditional CD40 Agonistic Antibodies Anna Säll, Senior Scientist, Alligator Bioscience, Swed	17:30 - 18:00
Closing remarks from the Chairman Andrea Bisso, Director of Pharmacology , Gadeta	18:00 - 18:00
Drinks Reception and Networking	18:00 - 18:00
End of Day 1	18:00 - 18:00

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening remarks from the Chairman Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK	08:55 - 09:00
New Immune Checkpoints, Biomarker and Tumour Microenvironment
Keynote Presentation: The Gammabody platform: novel gamma-delta T cell engagers for treating cancer Paul Parren, EVP and Head of R&D, Lava Therapeutics	09:00 - 09:30
Veracyte Biopharma Atlas, a comprehensive cancer reference database Valerie Balme, Associate Director, Business Development, Veracyte	09:30 - 10:00
Combination Immunotherapies Delivered to Solid Tumour Microenvironment’s with the Tumour Specific Immunogene Platform. Samantha Bucktrout, Vice President, Research Strategy, PsiOxus Therapeutics	10:00 - 10:30
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:30 - 11:15
Cancer Immunotherapy: accelerating preclinical drug candidate selection using humanized mouse models with advanced immune systems in vivo and in vitro Sebastien Tabryun, Chief Scientific Officer, TransCure bioServices	11:15 - 11:45
Modulation of the tumour microenvironment with IgE immunotherapy Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK	11:45 - 12:15
Immunology Methylation Panel Devloped and Validated Using Targeted Bisulfite NGS Sarah Miller, Senior Research Associate, EpigenDx	12:15 - 12:45
Effective in situ vaccination with oncolytic molecules in combination with cell therapy and immune checkpoint inhibitors Øystein Rekdal, CEO, Lytix Biopharma	12:45 - 13:15
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:15 - 14:15
PeptiCRAd platform as a novel intratumoral fusion immunotherapy targeting heterogeneous antigen profile of solid tumors Sari Pesonen, Co-Founder, Head, R&D, Valo Therapeutics	14:15 - 14:45
Involvement of posttranslational modified neoepitopes (PTM) in diseases Ahuva Nissim, Professor, Antibody and Therapeutic Engineering, Queen Mary University of London	14:45 - 15:15
ON203: A new antibody targeting the oxidized form of macrophage migration inhibitory factor (oxMIF) exerts antitumorigenic activity and modulates the tumor microenvironment. Barbara Maurer, Senior Scientist, OncoOne	15:15 - 15:45
Enhancing the Targeting Specificity of Existing Therapeutic Antibodies Colin Self , CEO, Precision ImmunoTherapeutics	15:45 - 16:15
Closing remarks from the Chairman Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK	16:15 - 16:20
End of Conference	16:20 - 16:20